Chief Business Officer, Strata Oncology, Inc.
Catherine is a global executive and board member, deeply experienced in complex, highly-regulated industry, and achieving growth and change through roles with far more accountability than authority. She is an independent director and member of the Audit Committee of the Board of Directors of Meridian Bioscience, Inc., a public diagnostics and life sciences company (NASDAQ: VIVO), and serves on the Advisory Board of Neurocern, Inc., a private dementia management system company. She currently serves as Chief Business Officer at Strata Oncology, Inc., a private precision oncology company, where she leads corporate and business development, marketing, public relations and legal functions as part of the core senior executive team. In addition, Catherine is a member of Chicago Innovation Mentors @ MATTER, mentoring healthcare startups and in the broader community of academic and clinical research institutions.
Prior to Strata Oncology, Catherine held senior global roles at Takeda Pharmaceuticals (4502: Tokyo) and Abbott Laboratories (pre-split NYSE: ABT, covering pharmaceuticals, diagnostics, medical devices and nutritionals businesses world-wide) in corporate and business development, legal, compliance, and finance. She led strategy development and all transactional aspects in transformative M&A for both companies (e.g., Takeda $13B acquisition of Nycomed S.A. for global expansion; Takeda $9B acquisition of Millennium Pharmaceuticals for enhanced oncology presence; Abbott $7B acquisition of Knoll Laboratories, adding global presence and assets including mega- blockbuster Humira®). She also led business development strategy and execution across multiple therapeutic areas such as CNS, cardiovascular, metabolic, GI, renal, vaccines, respiratory and immunology, leading global crossfunctional teams and continuing to take hands-on responsibility for structuring, negotiation and governance of critical M&A and partnerships.
Catherine has also led global change through restructuring and organization design (e.g., achieving WW recurring savings of >$500 MM for Takeda while reporting to Global CFO; leading global organization design, build, and management of 50+ global staff in Abbott Office of Ethics & Compliance); conducted enterprise risk assessments and internal investigations; opened ex-US affiliates; and led strategy and execution of successful litigation including
antitrust, IP, employment, mass tort, shareholder and government actions.
She received a B.A. from the University of Notre Dame and a J.D. from Northwestern University School of Law.